Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group* †

Summary
Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care.

Methods In a randomised, double-blind, phase 3, placebo-controlled trial, adults with symptoms for up to 12 days and hospitalised for COVID-19 at 81 sites in the USA, Europe, Uganda, and Singapore were randomly assigned in a 1:1 ratio to receive intravenous tixagevimab 300 mg–cilgavimab 300 mg or placebo, in addition to remdesivir and other standard care. Patients were excluded if they had acute organ failure including receipt of invasive mechanical ventilation, extracorporeal membrane oxygenation, vasopressor therapy, mechanical circulatory support, or new renal replacement therapy. The study drug was prepared by an unmasked pharmacist; study participants, site study staff, investigators, and clinical providers were masked to study assignment. The primary outcome was time to sustained recovery up to day 90, defined as 14 consecutive days at home after hospital discharge, with co-primary analyses for the full cohort and for participants who were neutralising antibody-negative at baseline. Efficacy and safety analyses were done in the modified intention-to-treat population, defined as participants who received a complete or partial infusion of tixagevimab–cilgavimab or placebo. This study is registered with ClinicalTrials.gov, NCT04501978 and the participant follow-up is ongoing.

Findings From Feb 10 to Sept 30, 2021, 1455 patients were randomly assigned and 1417 in the primary modified intention-to-treat population were infused with tixagevimab–cilgavimab (n=710) or placebo (n=707). The estimated cumulative incidence of sustained recovery was 89% for tixagevimab–cilgavimab and 86% for placebo group participants at day 90 in the full cohort (recovery rate ratio [RRR] 1·08 [95% CI 0·97–1·20]; p=0·21). Results were similar in the seronegative subgroup (RRR 1·14 [0·97–1·34]; p=0·13). Mortality was lower in the tixagevimab–cilgavimab group (61 [9%]) versus placebo group (86 [12%]; hazard ratio [HR] 0·70 [95% CI 0·50–0·97]; p=0·032). The composite safety outcome occurred in 178 (25%) tixagevimab–cilgavimab and 212 (30%) placebo group participants (HR 0·83 [0·68–1·01]; p=0·059). Serious adverse events occurred in 34 (5%) participants in the tixagevimab–cilgavimab group and 38 (5%) in the placebo group.

Interpretation Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower.

Funding US National Institutes of Health (NIH) and Operation Warp Speed.

Copyright © 2022 Elsevier Ltd. All rights reserved.

Introduction Neutralising monoclonal antibodies targeting SARS-CoV-2 are effective for treatment of early COVID-19 among outpatients with risk factors for progression to severe illness, as well as for primary prevention and post-exposure prophylaxis. Hospitalised patients might also benefit from neutralising monoclonal antibodies, although previous results have varied by agent and serostatus. Monoclonal antibody effectiveness is threatened, however, by the emergence of new SARS-CoV-2 variants.

Tixagevimab–cilgavimab (AZD7442 [Evusheld], consisting of AZD8895 and AZD1061; AstraZeneca) is a combination of two Fc-modified human monoclonal antibodies derived from B cells from two individuals who had recovered from SARS-CoV-2 infection. These antibodies recognise non-overlapping sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein. The Fc-modifications extend half-life and reduce FcR and C1q complement binding to minimise the theoretical risk of antibody-dependent enhancement of disease. The ACTIV-3–TICO (Accelerating COVID-19 Therapeutic Interventions and Vaccines–Therapeutics for Inpatients with COVID-19) platform protocol evaluates promising antiviral therapies among patients hospitalised with COVID-19, for whom outcomes, including mortality,
remain poor. The first three monoclonal antibody products studied were halted at the early futility analyses on the basis of a seven-category ordinal scale for pulmonary function, as described previously. Here we report the results of the ACTIV-3–TICO trial comparing tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care. Tixagevimab–cilgavimab did not improve the primary endpoint of sustained patient recovery, but it was safe and led to a clinically relevant reduction in mortality. The mortality signal was numerically larger in patients requiring high-flow oxygen or non-invasive mechanical ventilation at study entry and in patients infected with the delta SARS-CoV-2 variant. In contrast to some previous monoclonal antibody studies, there were no differences in any of the efficacy or safety study outcomes by baseline endogenous neutralising antibody serostatus.

Implications of all the available evidence
A single intravenous dose of tixagevimab–cilgavimab might provide additional clinical benefits to current standard care in patients hospitalised with COVID-19. Benefits might actually be greatest in patients with more advanced respiratory failure. The mortality reduction observed in this study belong to a secondary endpoint and thus requires additional validation. As baseline serostatus was not associated with efficacy or safety outcomes, antibody testing might not be required to administer this treatment.

Methods

Study design
The TICO platform protocol outlines the testing of multiple candidate antiviral therapies via a phase 3 multi-arm, multistage, double-blind, randomised controlled trial design at 81 sites in the USA, Europe, Uganda, and Singapore (see appendix p 30). The protocol was approved by a governing institutional review board for each enrolling site. Written informed consent for trial participation was obtained from each enrolled patient or a legally authorised representative, as applicable.

Study participants
Adult, hospitalised patients were eligible if they had confirmed SARS-CoV-2 infection and symptoms for up to 12 days. Patients were excluded if they had acute organ failure including receipt of invasive mechanical ventilation, extracorporeal membrane oxygenation, vasopressor therapy, mechanical circulatory support, or new renal replacement therapy. At the beginning of the trial (Feb 10, 2021), patients on high-flow nasal oxygen or non-invasive ventilation were excluded. On July 19, 2021, after 743 (51%) of 1455 patients were enrolled, eligibility was expanded at the recommendation of the US Food and Drug Administration and data and safety monitoring board (DSMB) to include these patients. A full list of eligibility criteria and rationale for change during the trial is provided in the appendix (pp 17, 18).

Randomisation and masking
Participants were enrolled by study investigators or a designee. Hospitalised adults with COVID-19 were randomly assigned in a 1:1 ratio to either tixagevimab 300 mg–cilgavimab 300 mg or placebo. Randomisation was done via an interactive web-based application with a computer-generated random sequence and was stratified by study site pharmacy. Study drug was prepared by an unmasked pharmacist on site; study participants, site study staff, investigators, and clinical providers were masked to trial group assignment. Masking was further assured by placing a coloured sleeve over the infusion bags used for tixagevimab–cilgavimab and placebo.

Procedures
Tixagevimab and cilgavimab were derived from convalescent B cells from two COVID-19 survivors.
They are both YTE (M257Y, S259T, T261E) modified isoforms to extend their half-life and therapeutic treatment window.17,18 Additionally, their Fc regions have three amino acid substitutions (L234F, L235E, P331S) that reduce binding to human Fc receptors and C1q to minimise the theoretical risk of Fc- or complement-mediated antibody-dependent enhanced disease.19

Adults hospitalised with COVID-19 were randomly assigned in a 1:1 ratio to either tixagevimab 300 mg–cilgavimab 300 mg, administered as a single intravenous infusion over a 30-min period, or placebo (appendix p 16).

Presence of anti-spike SARS-CoV-2 neutralising plasma antibody at baseline was centrally measured by batch on cryopreserved plasma by means of the GenScript SARS-CoV-2 Surrogate Virus Neutralization Test (GenScript, Piscataway, NJ, USA) with 30% binding inhibition to define positivity per manufacturer specifications. Additional plasma antibody (BioRad Platelia, Hercules, CA, USA; Quanterix Simoa, Billerica, MA, USA) and antigen (Quanterix Simoa) assays are detailed in the appendix (pp 22, 23).

Remdesivir was provided to all study participants unless contraindicated. Receipt of exogenous SARS-CoV-2 antibodies (eg, other monoclonal antibody products, convalescent plasma, or hyperimmune globulin) was prohibited. Corticosteroids were encouraged for participants with hypoxaemia. Other medications were permitted as part of locally determined standard of care. National Institutes of Health (NIH) treatment guidelines were encouraged but not required by the protocol.22

Outcomes
The primary outcome was time from randomisation to sustained clinical recovery up to day 90, defined as return to home for 14 consecutive days (with home defined as the participant’s residence type before hospitalisation or a location that provided similar or less intensive medical care). This outcome captures patient-centred, clinically important events after hospital discharge, given that hospital discharge might occur quickly particularly during pandemic conditions and the omission of post-discharge events might underestimate disease burden. Key secondary efficacy outcomes included all-cause mortality up to day 90 and a composite of sustained recovery and mortality up to day 90. Other secondary outcomes are seven-category pulmonary ordinal outcome scale, a seven-category pulmonary-plus ordinal outcome scale, time to discharge from the index hospitalization, a composite safety outcomes through days 5, 28 and 90, reactions associated with the infusion of the study treatments (appendix pp 26–29).

Remdesivir was provided to all study participants unless contraindicated. Receipt of exogenous SARS-CoV-2 antibodies (eg, other monoclonal antibody products, convalescent plasma, or hyperimmune globulin) was prohibited. Corticosteroids were encouraged for participants with hypoxaemia. Other medications were permitted as part of locally determined standard of care. National Institutes of Health (NIH) treatment guidelines were encouraged but not required by the protocol.22

Outcomes
The primary outcome was time from randomisation to sustained clinical recovery up to day 90, defined as return to home for 14 consecutive days (with home defined as the participant’s residence type before hospitalisation or a location that provided similar or less intensive medical care). This outcome captures patient-centred, clinically important events after hospital discharge, given that hospital discharge might occur quickly particularly during pandemic conditions and the omission of post-discharge events might underestimate disease burden. Key secondary efficacy outcomes included all-cause mortality up to day 90 and a composite of sustained recovery and mortality up to day 90. Other secondary outcomes are seven-category pulmonary ordinal outcome scale, a seven-category pulmonary-plus ordinal outcome scale, time to discharge from the index hospitalization, a composite safety outcomes through days 5, 28 and 90, reactions associated with the infusion of the study treatments (appendix pp 26–29).

The main safety outcome was a composite of death, serious adverse events, incident organ failure, and serious co-infections up to day 90. A local site investigator graded all adverse events for severity using the toxicity table of the Division of AIDS from the National Institute of Allergy and Infectious Diseases, version 2.1. Adverse events were
categorised according to codes in the Medical Dictionary for Regulatory Activities (MedDRA), version 23.1 and grouped by system organ class; definitions, timing, and additional outcomes are described in the appendix (pp 26–29).

### Statistical analysis

The study was initially planned to provide 90% power to detect a recovery rate ratio (RRR) of 1:25 (25% improved rate of sustained recovery in the tixagevimab–cilgavimab group compared with placebo) at the 0.05 (two-sided) level of significance. This required 843 primary events (ie, participants who achieved sustained recovery), which was estimated to be achieved with 1000 participants. Motivated by the results of other trials suggesting that participants without endogenous SARS-CoV-2 antibodies at baseline (seronegative) might benefit from neutralising monoclonal antibody treatment, whereas seropositive participants might not benefit and might even be harmed, the study was amended on Aug 19, 2021, to provide 90% power to detect an RRR of 1:20 overall and of 1:28 among seronegative participants. On the basis of intermediate pooled data, this was estimated to achieve with 1228 primary events wherein 56% would be seronegative and contribute 545 events.

The primary analysis tested hypotheses for the primary outcome in the full cohort and the seronegative subgroup simultaneously as co-primary. Holm’s method was used to control family-wise type 1 error at 0.05 by first testing the hypothesis with the lower p value at the 0.025 (two-sided) level of significance and then if significant, the hypothesis with the higher p value at 0.05. Power estimates were updated on the basis of the final enrolment and analysis plan (appendix p 23). There was no adjustment for multiple comparisons of secondary outcomes.

The primary analysis was modified intention-to-treat, restricted to participants who received a complete or partial infusion of tixagevimab–cilgavimab or placebo. Because treatment assignment was blinded, the reasons for not receiving an infusion were independent from the treatment assignment. For the primary outcome of sustained recovery, participants who were alive but had not had sustained recovery were censored at the last date on which the endpoint status was ascertained. Participants who withdrew consent were censored at the date of withdrawal. We compared treatment groups for time to sustained recovery using a Fine-Gray model (accounting for the competing risk of death), stratified by study site pharmacy and country (7 strata total). We compared death and composite safety outcomes up to day 90 using stratified Cox proportional hazards models and a composite of sustained recovery and mortality using the win-ratio method (appendix p 24).

RRR greater than 1 denotes superiority of tixagevimab–cilgavimab compared with placebo on the cumulative incidence of sustained recovery. Treatment comparisons by means of Cox proportional hazards models are presented such that hazard ratios (HRs) less than 1 (for death and safety outcomes) denote superiority of tixagevimab–cilgavimab. Additional preplanned subgroup and secondary analyses are described in the appendix (pp 26–29). We did all statistical analyses using SAS (version 9.4) and R (version 4.1). The trial was overseen by an independent DSMB who evaluated unmasked interim data for futility, efficacy, and safety. This study is registered with ClinicalTrials.gov, NCT04501978.

### Role of the funding source

The Division of Clinical Research at the National Institute of Allergy and Infectious Diseases funded this project. Investigators from NIH were directly involved in all aspects of this study, including study design, data collection, data analysis, data interpretation, writing of the report, and the decision to submit.

### Results

From Feb 10 to Sept 30, 2021, we enrolled 1455 patients at 81 sites in the USA, Europe, Uganda, and Singapore. The primary analysis population included 1417 patients who received a complete or partial infusion of tixagevimab–cilgavimab (n=710) or placebo (n=707;...
Table 2: Main outcomes for primary cohort and by baseline neutralising antibody status

| Combination                  | Full cohort | Co-primary, sustained recovery up to day 90†‡ | Censored | Died before sustained recovery | Death up to day 90 | Composite safety outcome up to day 90§ | Serious adverse event | Death or serious adverse event | Death, serious adverse event, or organ failure | Anti-spike neutralising antibody negative¶ | Anti-spike neutralising antibody positive¶ |
|------------------------------|-------------|-----------------------------------------------|----------|---------------------------------|-------------------|-----------------------------------------|-----------------------|----------------------------------|-------------------------------------------|---------------------------------|---------------------------------|
| Tixagevimab–cilgavimab group (n=710) |             | 617 (89%)                                      | 34 (5%)  | 59 (8%)                         | 61 (9%)          | 128 (25%)                                | 34 (5%)               | 85 (12%)                        | 166 (23%)                          | n=307                           | n=380                           |
| Placebo group (n=707)        |             | 595 (86%)                                      | 31 (4%)  | 81 (11%)                        | 86 (12%)         | 212 (30%)                                | 38 (5%)               | 112 (16%)                       | 200 (28%)                          |                                  |                                  |
| Rate or hazard ratio* (95% CI) |             | 1.08 (0.97–1.20)                               | ..       | ..                              | 0.70 (0.50–0.97) | 0.83 (0.68–1.01)                          | ..                    | ..                              | ..                             | 1.14 (0.97–1.34) | 0.81 (0.62–1.08) |
| p value                      |             | 0.21                                           | ..       | ..                              | 0.032             | 0.059                                    | ..                    | ..                              | ..                             | 0.13                                           | 0.15                              |

*Recovery rate ratio or hazard ratio, according to the methods and statistical analysis plan in the appendix (p 16). Recovery rate ratios of >1 for sustained recovery and hazard ratios of <1 for death and safety endpoints favour tixagevimab–cilgavimab. †Co-primary outcomes analysed by Holm’s method to control familywise type 1 error at 0.05, according to the methods and statistical analysis plan in the appendix (p 16). ‡Based on the estimated cumulative incidence of sustained recovery, which was 78% for tixagevimab–cilgavimab and 76% for placebo group participants at day 28 and 89% and 86%, respectively, at day 90 (figure 2). §Composite of death, serious adverse events, incident organ failure, and serious co-infection. ¶Neutralising antibody status determined by GenScript cPass surrogate SARS-CoV-2 neutralisation assay (anti-spike); positive was defined as ≥30% binding inhibition. Available for 1363 of 1417 participants in the full cohort.
Baseline characteristics were balanced between groups and the overall study group was generally representative of patients hospitalised with COVID-19 (table 1, appendix pp 32–37). The median duration of symptoms at enrolment was 8 days (6–10), 1041 (73%) were unvaccinated, and 128 (9%) were immunocompromised including 56 (4%) taking anti-rejection medications. Common pre-randomisation medications administered included remdesivir (897 [63%]) and corticosteroids (1035 [73%]; table 1, appendix pp 34, 35). Including those who initiated therapy after study infusion, 1315 (93%) participants received remdesivir. Anti-spike neutralising antibodies were not detectable at baseline for 644 (47%) of 1363 participants (ie, they were seronegative), whereas 1287 (94%) of 1363 had detectable plasma SARS-CoV-2 nucleocapsid antigen concentrations. On the basis of PCR data, 687 (51%) of 1347 were infected with the delta SARS-CoV-2 variant, of which 648 (94%) were enrolled July–September, 2021.

The estimated cumulative incidence of sustained recovery was 78% for the tixagevimab–cilgavimab group and 76% for the placebo group participants at day 28 and 89% and 86%, respectively, at day 90 for the full cohort (RRR 1·08 [95% CI 0·97–1·20]; p=0·21; table 2, figure 2). Results were similar in the seronegative subgroup (RRR 1·14 [0·97–1·34]; p=0·13; table 2; figure 3). Results were not materially different in a sensitivity analysis that defined sustained recovery as both being at home and no longer on new supplemental oxygen for 14 consecutive days (data not shown).

Figure 3: Time to sustained recovery and death up to day 90 by baseline serostatus
(A) Sustained recovery for seronegative cohort. (B) Sustained recovery for seropositive cohort. (C) Death for seronegative cohort. (D) Death for seropositive cohort.
RRR and HR calculated according to methods and statistical analysis plan in the appendix (p 23). RRR >1 for sustained recovery and HR <1 for death favour tixagevimab–cilgavimab. By definition, sustained recovery can be achieved no earlier than 14 days after randomisation. HR=hazard ratio. RRR=recovery rate ratio.
Up to day 90, death occurred in 61 (9%) participants in the tixagevimab–cilgavimab group compared with 86 (12%) in the placebo group in the full cohort (HR 0·70 [95% CI 0·50–0·97]; p=0·032; table 2; figure 2); estimates were similar in the seronegative subgroup (29 [9%] vs 45 [13%]; HR 0·70 [0·44–1·12]; p=0·14; table 2; figure 3). In the composite analysis of sustained recovery and death, tixagevimab–cilgavimab outcomes were not significantly different from placebo (win ratio 1·08 [95% CI 0·92–1·27], p=0·33 for overall cohort; 1·16 [0·92–1·47], p=0·21 for the seronegative subgroup; appendix p 40).

The proportion of participants across the pulmonary ordinal scale categories was not statistically different between treatment groups at day 5 (odds ratio [OR] 1·06 [95% CI 0·88–1·29]; p=0·52) and day 14 (OR 1·16 [0·95–1·42]; p=0·015), but favoured tixagevimab–cilgavimab at day 28 (OR 1·28 [1·03–1·59], p=0·024; figure 4). Tixagevimab–cilgavimab was generally well tolerated with low rates of treatment-emergent adverse events (appendix pp 43–53). Infusion reactions were relatively uncommon and similar in the tixagevimab–cilgavimab (41 [6%]) and placebo (48 [7%]) groups and were mostly of grade 1 or 2 in severity (appendix pp 43, 44).

The main safety outcome (composite of death, serious adverse events, incident organ failure, and serious co-infection through day 90) occurred in 178 (25%) participants in the tixagevimab–cilgavimab group and 212 (30%) in the placebo group (HR 0·83 [95% CI 0·68–1·01]; p=0·059; table 2, appendix pp 54–55).

Serious adverse events occurred in 34 (5%) participants in the tixagevimab–cilgavimab group and 38 (5%) in the placebo group (table 2, appendix pp 49–53). Most safety events were classified as respiratory–thoracic–mediastinal, gastrointestinal, nervous system, or general system organ classification. A similar proportion of participants in both groups experienced cardiovascular, thromboembolic, and renal adverse events.

The presence of anti-SARS-CoV-2 antibodies at baseline measured by three assays (two anti-spike, one anti-nucleocapsid) did not substantively modify the effect of tixagevimab–cilgavimab on time to sustained recovery, death, or the composite safety outcome (appendix pp 45–48, 58–64). Since SARS-CoV-2 vaccination might influence baseline serostatus, we did a post-hoc analysis for unvaccinated participants only; results stratified by baseline serostatus were similar (appendix pp 43, 66). The treatment effect also did not vary substantially by geographical region, SARS-CoV-2 vaccination status, or immunocompromised state (appendix pp 54–62; figure 5). For sustained recovery and deaths up to day 90, point estimates of RRRs and HRs favoured earlier treatment with tixagevimab–cilgavimab for those within 9 days of symptom onset, participants infected with the delta variant, and those receiving high-flow nasal oxygen or non-invasive ventilation at baseline (figure 5, appendix pp 56–67).

**Discussion**

In this multinational phase 3 trial involving patients hospitalised with COVID-19, treatment with a single infusion of tixagevimab–cilgavimab, compared with placebo, did not improve the primary outcome of time to sustained recovery, but led to a 30% relative risk reduction for mortality up to day 90. Absolute risk reduction was 3–6%. In contrast to earlier results with other monoclonal antibody treatments that showed more favourable results for seronegative than seropositive patients, results for tixagevimab–cilgavimab did not differ by baseline serostatus. There was also no evidence of harm either overall or by baseline serostatus. Taken together, these results suggest that tixagevimab–cilgavimab is safe and might reduce mortality among patients hospitalised with COVID-19. The reason for different results for sustained recovery and mortality might be related to the relatively high proportion of participants receiving no or low (<4 L/min) supplemental oxygen (59%), who tended to recover quickly with remdesivir and other standard care, or might be due to chance.

Outcomes with tixagevimab–cilgavimab differ from previous monoclonal antibodies in several ways. Tixagevimab–cilgavimab is the first in the ACTIV-3 platform that the DSMB recommended to proceed to full
enrolment after early futility assessment and also the first to ultimately suggest lower mortality. Whereas two of the three agents previously studied were associated with possible harm in patients who are seropositive, as was casirivimab–imdevimab in the RECOVERY trial but not in a company sponsored trial, a safety signal was not observed with tixagevimab–cilgavimab in this subgroup, despite an approximately 90-day half-life that is longer than previous monoclonal antibodies. It is unknown whether this different result is attributable to the specific epitopes targeted by tixagevimab–cilgavimab or the Fc modifications that might reduce potential risk of antibody dependent enhancement of disease, versus changes over time in patients (such as vaccination), viral variants, or other epidemiological factors. More generally, these discordant results suggest that potential harm in patients who are seropositive is not a class-wide effect among all monoclonal antibodies.

As with other antiviral therapies, treatment earlier in the COVID-19 disease course might be more likely to be beneficial. This is illustrated by subgroup analyses for time to sustained recovery up to day 90 in Figure 5.}

Figure 5: Subgroup analysis for time to sustained recovery up to day 90 for the full cohort
Continuous variables interaction p values are based on them being fitted as continuous rather than categorical. For baseline pulmonary category, participants were eligible for enrolment in the HFNC or NIV group, only after July 19, 2021; this corresponds to a pandemic phase when the delta variant was predominant.

HFNC=high-flow nasal cannula. NIV=non-invasive ventilation. RRR=recovery rate ratio.

| Age* (years) | Tixagevimab–cilgavimab | Placebo | Recovery rate ratio (95% CI*) | Interaction p value |
|--------------|-------------------------|---------|-------------------------------|-------------------|
| Patients     | Events (%)              | Patients | Events (%)                    |                   |
| <50          | 255 239 (94%)           | 259 233 (90%)      | 1.01 (0.86–1.20)             | 0.047             |
| 50–59        | 181 157 (87%)           | 171 157 (92%)      | 0.85 (0.69–1.05)             |                   |
| 60–69        | 141 119 (84%)           | 159 126 (79%)      | 1.34 (1.06–1.71)             |                   |
| 70–79        | 99 78 (79%)             | 73 55 (75%)        | 1.14 (0.82–1.58)             |                   |
| ≥80          | 34 24 (71%)             | 45 24 (53%)        | 1.42 (0.83–2.44)             |                   |
| Gender       |                         |                     |                               | 0.69              |
| Male         | 411 355 (86%)           | 412 344 (83%)      | 1.06 (0.92–1.22)             |                   |
| Female       | 299 262 (88%)           | 295 251 (85%)      | 1.10 (0.94–1.30)             |                   |
| Race         |                         |                     |                               | 0.29              |
| Black        | 177 149 (84%)           | 175 150 (86%)      | 0.94 (0.76–1.16)             |                   |
| Hispanic     | 119 102 (86%)           | 135 112 (83%)      | 1.05 (0.82–1.36)             |                   |
| White or other | 414 366 (88%)          | 397 333 (84%)      | 1.15 (1.00–1.32)             |                   |
| Region       |                         |                     |                               | 0.91              |
| Africa       | 43 33 (77%)             | 45 35 (78%)        | 1.01 (0.65–1.58)             |                   |
| Asia         | 13 12 (92%)             | 10 9 (90%)         | 1.18 (0.49–2.83)             |                   |
| Europe       | 135 128 (95%)           | 130 118 (91%)      | 1.04 (0.82–1.31)             |                   |
| North America | 519 444 (86%)          | 522 433 (83%)      | 1.09 (0.97–1.24)             |                   |
| Days since symptom onset* |       |                     |                               | 0.27              |
| ≥5           | 146 124 (85%)           | 151 122 (81%)      | 1.20 (0.95–1.51)             |                   |
| 6–8          | 243 215 (88%)           | 270 224 (83%)      | 1.17 (0.98–1.40)             |                   |
| <5           | 321 278 (87%)           | 286 249 (87%)      | 0.94 (0.80–1.10)             |                   |
| Baseline pulmonary category* |       |                     |                               | 0.57              |
| Not on supplementary O2 | 174 163 (94%)   | 155 141 (92%)      | 1.08 (0.88–1.32)             |                   |
| Supplementary O2, flow rate <4 L/min | 241 222 (92%) | 229 246 (91%)      | 1.06 (0.90–1.25)             |                   |
| Supplementary O2, flow rate ≥4 L/min | 216 177 (82%) | 200 161 (81%)      | 1.03 (0.84–1.26)             |                   |
| HFNC or NIV  | 79 55 (70%)             | 82 45 (55%)        | 1.48 (1.01–2.18)             |                   |
| SARS-CoV-2 vaccination status |       |                     |                               | 0.90              |
| Fully vaccinated | 103 85 (83%)  | 101 78 (77%)       | 1.10 (0.82–1.48)             |                   |
| Partially vaccinated | 82 72 (88%)  | 90 78 (87%)       | 1.14 (0.85–1.54)             |                   |
| Not vaccinated | 525 460 (88%)          | 516 433 (85%)      | 1.06 (0.94–1.20)             |                   |
| Immunosuppressed | 57 43 (75%) | 71 53 (75%)       | 0.91 (0.62–1.34)             |                   |
| No           | 653 574 (88%)           | 636 542 (85%)      | 1.09 (0.83–1.42)             |                   |
| Delta PCR result |       |                     |                               | 0.21              |
| Delta variant | 344 288 (84%)          | 343 271 (79%)      | 1.17 (1.00–1.37)             |                   |
| Not Delta variant | 341 308 (90%)          | 339 284 (89%)      | 1.01 (0.87–1.17)             |                   |

*Recovery rate ratio from Fine–Gray model
The interaction p value for asterisked subgroups is for trend (across measured value)
In the present trial, almost all participants still had detectable viral antigen concentrations at baseline (median 8 days of symptoms), and nearly half did not have endogenous neutralising antibodies, suggesting that antivirals might remain an important component of the treatment approach in patients who are hospitalised. This result aligns with the first stage of the Adaptive COVID-19 Treatment Trial, in which treatment with the antiviral remdesivir was beneficial in patients enrolled at a median of 9 days, as well as with the RECOVERY trial, in which casirivimab–imdevimab showed a mortality reduction in patients who had been hospitalised who were seronegative at a median of 7 days of symptoms. Additionally, tixagevimab–cilgavimab was evaluated with concomitant remdesivir, in contrast to the RECOVERY trial in which only approximately 25% of patients received remdesivir. Although there are conflicting guidelines regarding its use for patients hospitalised with COVID-19, concomitant remdesivir treatment in this trial ensures that any observed benefits of tixagevimab–cilgavimab are additive to this background antiviral therapy. In RECOVERY, 28-day mortality was 20% compared with 10% in the current study. The results from the present trial suggest that monoclonal antibodies might provide clinical benefit in patients irrespective of whether they are receiving a direct-acting antiviral agent. As this benefit was not apparent with the pulmonary ordinal scale at day 5 (used for early futility assessment in all TICO trials), future clinical trials in inpatients with COVID-19 might be best served by assessing early futility by means of a later timepoint, a different outcome, or both.

Strengths of this trial include a large, diverse patient population enrolled at experienced sites on four continents. Additionally, there was blinded administration of the investigational agent, detailed attention to outcome ascertainment, and continuous review from the DSMB. Although ACTIV-3/TICO is a multi-arm platform, patients were randomly assigned to only one investigational agent and contemporaneous placebos were used, so the results are not influenced by other investigational agents. Although underpowered for subgroup analyses, there was no compelling evidence of differences between tixagevimab–cilgavimab and placebo in either efficacy or safety by baseline serostatus, region, comorbid conditions, including immunocompromised state, or by vaccination status, suggesting that the results are broadly generalisable. The potential for benefit in patients receiving high-flow nasal cannula or mechanical ventilation merits further study.

Our trial has several limitations. First, enrolment concluded before the emergence of the omicron variant, so we do not have direct evidence for patients infected with this or future variants. However, in vitro data suggest that although the half maximal inhibitory concentration (IC50) for tixagevimab–cilgavimab is higher against the omicron (B.1.1.529 or BA.2) variant as compared with previous variants, clinical activity might be retained, albeit higher doses might be required. Second, only a minority of participants were fully vaccinated, making it difficult to extrapolate our results to vaccinated or boosted patients. Third, critically ill patients already requiring mechanical ventilation, vasopressors, or new renal replacement therapy were excluded. Reassuringly, nominal differences for efficacy and safety favoured tixagevimab–cilgavimab for participants receiving high-flow nasal cannula or non-invasive ventilation at baseline. Fourth, since almost all patients received remdesivir per protocol, the benefit of tixagevimab–cilgavimab if used as antiviral monotherapy is unknown. Broad adherence to guideline-recommended treatment, including remdesivir and corticosteroids, might reduce the potential for larger effect sizes, and the study had limited power to detect a modest treatment effect for sustained recovery. Yet, the observed mortality benefit highlights the ongoing need for further rescue interventions for patients hospitalised with COVID-19.

A single infusion of tixagevimab–cilgavimab, added to background therapy with remdesivir and other standard care, did not reduce time to the primary outcome of sustained recovery among patients hospitalised with COVID-19. However, this combination monoclonal antibody was safe and resulted in a 30% lower mortality than standard care alone, suggesting that tixagevimab–cilgavimab might be a useful treatment option for patients hospitalised with COVID-19.
University Medical Center; Nashville, Tennessee, USA (W H Self MD); The Kirby Institute, University of New South Wales; Sydney, Australia (C C Chang MD); Washington DC VA Medical Center Washington DC, USA (A Sánchez MS); Infectious Diseases Section, Washington, DC VA Medical Center, Washington DC, USA (A C Weintrob MD); Lundquist Institute and Harbor-UCLA Medical Center, Torrance, CA, USA (T Harlen MD); School of Statistics, University of Minnesota; Minneapolis, Minnesota, USA (Prof B Grund PhD); Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA (S Sharma MS, Prof C S Reilly PhD); AstraZeneca, Gaithersburg, MD, USA (P Garbes MD, M T Esler PhD); AstraZeneca, Cambridge, UK (A Templeton PhD); The Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK (A G Babiker PhD); United States Department of Veterans Affairs, Washington DC, USA (V J Davey PhD); Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA (Prof A C Geligins PhD); National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA (E S Higgs MD); Infectious Diseases Section, VA Medical Center, Washington DC, USA (Prof V Kan MD); The Kirby Institute, University of New South Wales; Sydney, Australia (Prof G Matthews MRCP); Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (Prof B Taylor Thompson MD); Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA (Prof J D Neaton PhD); National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA (H C Lane MD); CHIP Center of Excellence for Health, Immunity, and Infections and Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark (Prof J D Lundgren MD)

**Contributors**

JDN, TAM, NE, and GG directly accessed and verified the underlying data. JDL, HCL, JDN, AGB, VJD, ACG, ESH, VK, and BTT were responsible for conceptualisation. All authors were responsible for the investigation and reviewing and editing the manuscript. JDN, TAM, NE, and GG were responsible for data curation. TAM, NE, and GG were responsible for formal analysis and JDN, AGB, VJD, ACG, VK, BTT, and JDL were responsible for funding acquisition. JDL, HCL, JDN, AGB, VJD, ACG, ESH, VK, and BTT were responsible for supervision.

**Declaration of interests**

TLH reports consulting fees from Lyosyvant, royalties for UpToDate topic authorship, and participation on a Staphylococcus Aureus Network Adaptive Platform Trial Data and Safety Monitoring Board (DSMB), outside of the submitted work. AAG reports grants from US National Institutes of Health (NIH) during the conduct of the study, grants from US Centers for Disease Control (CDC), US Department of Defense (DOD), AbbVie, and Faron Pharmaceuticals, and participation on a NIH DSMB, outside of the submitted work. RP reports grants from Gilead, Viiv, and MSD and consulting fees from Gilead, Viiv, and MSD. Theratechnologies, and Eli Lilly, outside of the submitted work.

TAM reports grants from National Institute of Allergies and Infectious Diseases (NIAID), NIH, and Lexoid, outside of the submitted work. GG reports partial salary support from NIH through the University of Minnesota during the conduct of the study. US reports grants from Viiv, Cytxdon, NIAID, and Cardiothoracic Surgical Trial Network, consulting fees from ViiV and Shionogi, and payment for educational events from Paratek and Shionogi, outside of the submitted work. RLG reports contracts from Regeneron, consulting fees from Gilead and GSK Pharmaceuticals, participation on advisory boards for Eli Lilly, Gilead, GSK, Johnson and Johnson, Roche–Genentech, and Kinevant Sciences, de minimis stock in AbCellera, and receipt of medication from Gilead as an in-kind gift to facilitate the conduct of an academic-sponsored clinical trial, outside of the submitted work. MKJ reports grants from Gilead, participation on an advisory board for Gilead, and a Board of Director position with the HIV Medication Association, outside of the submitted work. LM reports payment for educational events from Merck, travel support from Merck and Gilead, and participation on an advisory board for Merck, outside of the submitted work. EM reports grants from NIAID and NIH, outside of the submitted work. KK reports grants and contracts with NIH, Regeneron, Abbott, Pfizer, Roamer, and Raisonne, consulting fees from Regeneron, travel support from Sanford Guide and Burroughs Wellcome Fund, and a pending patent for 3D swabs, and leadership positions at Sanford Guide and Burroughs Wellcome Fund, outside of the submitted work. PEM reports grants from NHLBI and NIH during the conduct of the study, grants and contracts from NHLBI and NIH, and consulting fees from Dompe, Medtronic, and Boehringer Ingelheim, outside of the submitted work. BT reports grants from VA Cooperative Studies Program Coordinating Center during the conduct of the study and grants and consulting fees from Genentech, outside of the study. KUK reports grants from NIH during the conduct of the study. MAM reports grants from NIH, DOD, the California Institute of Regenerative Medicine, Roche-Genentech, and Quantum Therapeutics and consulting fees from Novartis, Johnson and Johnson, Citius Pharmaceuticals, Pilant Therapeutics, and Gilead, outside of the submitted work. GP reports consulting fees from Menarini, Pfizer, MSD, and Gilead, payment for education events from Pfizer, MSD, AstraZeneca, and Gilead, and participation on advisory boards for Pfizer, Gilead, and MSD, outside of the submitted work. KNS reports consulting fees from Roche, Bristol Myers Squibb (BMS), Amgen, and MSD, outside of the submitted work. SRB reports consulting fees from Gilead, MSD, and GSK, payment for educational events from Gilead and MSD, and participation on advisory boards for Gilead, MSD, Pfizer, Roche, and Viiv, outside of the submitted work. JDN, TAM, and NIHDSMB, outside of the submitted work. PC reports grants from NIH during the conduct of the study and grants from Eli Lilly, Regeneron, and Gilead, consulting fees from Eli Lilly, Regeneron, and Gilead, and payment for education events from Frontline Collaborative, Physician Education Resource, Rockpointe, CME Outfitter, outside of the submitted work. DJD reports grants from NIH during the conduct of the study. DCF reports grants from NIH during the conduct of the study, grants from NIH and CDC, consulting fees from Cytovale, and participation on a DSMB for Medpace, outside of the submitted work. HFG reports grants from the Swiss National Science Foundation, Swiss HIV Cohort Study, Gilead, the Yvanne Jacob Foundation, and NIH and participation on advisory boards for Merck, Gilead, Viiv, Janssen, and Novartis, outside of the submitted work. RDH reports grants from NHLBI, Airway Therapeutics, Incyte Corporation, and Kiniksa Pharmaceuticals and participation on a NIH DSMB outside of the submitted work. AK reports grants from United Therapeutics, Johnson & Johnson, Eli Lilly, AstraZeneca, and 4DMedical, outside of the submitted work. JSO reports grants from NIH during the conduct of the study. JES reports grants from NIH during the conduct of the study. BEY reports consulting fees from Gilead and Novacyle and payment for educational events from AstraZeneca. Gilead, Sanofi, and Roche, outside of the submitted work. ANP reports grants from Bill and Melinda Gates Foundation (BGMF), UK Research and Innovation (UKRI), the Wellcome Trust, and the National Institute for Health and Care Research (NIHR) and consulting fees from BMGF, outside of the submitted work. DAM reports support from DNR1F26 during the conduct of the study. MLP reports grants from Boehringer-Ingelheim, payment for authorship from Genentech and France Foundation, and travel support from Eastern Pulmonary Conference, outside of the submitted work. DS reports salary support from NIH through Axle Informatics during the conduct of the study and a leadership position for EigenMed, outside of the submitted work. VN reports grants from NIH during the conduct of the study. SLP reports grants from the University of Minnesota during the conduct of the study and grants from Gilead, Viiv, Janssen, the European and Developing Countries Clinical Trials Partnership, the Medical Reserve Corps (MRC), and NIHR, and participation on a NIH DSMB, outside of the submitted work. JK reports grants from NIH during the conduct of the study and grants from NIH and participation on a DSMB for Hamilton, outside of the submitted work. WHS reports grants from NIH and NIHLSBI during the conduct of the study. BG reports grants from NIH during the conduct of the study. JS reports grants from NIH, outside of the submitted work. CSR reports grants from NIH during the conduct of the study. PG reports being an employee of AstraZeneca, being a full member of Academia de Medicina, Rio de Janeiro, Brazil, and stock ownership at Takeida. MTE reports stock ownership and being an employee at AstraZeneca. AT reports and stock ownership and being an employee at AstraZeneca.
employee at AstraZeneca. AGB reports grants from University of Minnesota, MRC, and UKRI during the conduct of the study. VJD reports grants from NIAID–NIH and a contract with the University of Minnesota, outside of the conduct of the study. GM reports grants from Gilead, AbbVie, and Viv, payment for a speaking engagement from Janssen, participation on advisory boards for AstraZeneca and Gilead, and a leadership role on the Australian National COVID-19 taskforce treatments committee, outside of the conduct of the study. BTT reports grants from NHI and consulting fees from Bayer, Novartis, and Thetis, outside of the conduct of the study. JDN reports grants from NIH and NIAID during the conduct of the study. All other members of the writing committee declare no competing interests.

Data sharing
Deidentified data from TICO trials will be made available 1 year after publication of final results from the platform. Supporting documents will be made available, including the protocol, statistical analysis plan, informed consent document, and data dictionary. Data will be made available to researchers after approval of a proposal for use of the data. Proposals for data use should be submitted by means of the research proposal form on the INSIGHT website.

Acknowledgments
We thank the members of the ACTIV-3–TICO data and safety monitoring board for their review of the protocol and their guidance based on interim reviews of the data. We also thank the participants and families whose dedication to contributing to science made this research study possible. The Division of Clinical Research at the National Institute of Allergy and Infectious Diseases funded this project. Investigators from NIH were directly involved in all aspects of this study, including study design, data collection, data analysis, data interpretation, and writing of the report. All analyses of biological material were done in a masked manner at laboratories affiliated with the funding source; data were sent to the statistical and data management center at the University of Minnesota for linkage to the trial database. Several representatives from the funding source are part of the writing group for the manuscript. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing official policies, either expressed or implied, of the National Institutes of Health or the Department of Veterans Affairs. Supported by the US Operation Warp Speed program, the National Institute of Allergy and Infectious Diseases and Leidos Biomedical Research for the INSIGHT Network, the National Heart, Lung, and Blood Institute and the Research Triangle Institute for and Leidos Biomedical Research for the INSIGHT Network, the National Speed program, the National Institute of Allergy and Infectious Diseases Department of Veterans Affairs. Supported by the US Operation Warp Speed

The views and conclusions contained in this document are those of the authors and should not be interpreted as representing official policies, either expressed or implied, of the National Institutes of Health or the Department of Veterans Affairs. Supported by the US Operation Warp Speed program, the National Institute of Allergy and Infectious Diseases and Leidos Biomedical Research for the INSIGHT Network, the National Heart, Lung, and Blood Institute and the Research Triangle Institute for the Prevention and Early Treatment of Acute Lung Injury Network and the Cardiothoracic Surgical Trials Network, the US Department of Veterans Affairs, and grants from the governments of Denmark, Australia, the UK, and Singapore. The research was, in part, funded by National Institutes of Health Agreement 1OT2HL156812-01 and National Australia, the UK, and Singapore. The research was, in part, funded by Veterans Affairs, and grants from the governments of Denmark, the Cardiothoracic Surgical Trials Network, the US Department of Heart, Lung, and Blood Institute and the Research Triangle Institute for and Leidos Biomedical Research for the INSIGHT Network, the National Speed program, the National Institute of Allergy and Infectious Diseases Department of Veterans Affairs. Supported by the US Operation Warp Speed.

References
1. Weirich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody combination and outcomes in outpatients with Covid-19. N Engl J Med 2021; 385: e81.
2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 2021; 384: 1941–50.
3. Dougan M, Nitula A, Aizaz M, et al. Bamlanivimab plus etesivanib in mild or moderate Covid-19. N Engl J Med 2021; 385: 1382–92.
4. US Food and Drug Administration. Letter of authorization for emergency use of EVUSHELD (tixagevimab and cilgavimab). Silver Spring, MD: US Food and Drug Administration, 2022. https://www.fda.gov/media/154704/download (accessed June 26, 2022).
5. O’Brien MP, Forleo-Neto E, Musser RJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med 2021; 385: 1184–93.
6. Cohen MS, Nitula A, Mulligan MJ, et al. Effect of Bamlanivimab vs Placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA 2021; 326: 46–55.
7. Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399: 665–76.
8. Lundgren JD, Grund B, Barkauskas CE, et al. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial. Ann Intern Med 2022; 175: 234–43.
9. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis 2022; 22: 622–35.
10. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron variant escapes neutralization by therapeutic monoclonal antibodies. Nat Med 2022; 28: 890–95.
11. Takashita E, Kinoshi N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant. N Engl J Med 2022; 386: 995–98.
12. US Food and Drug Administration Statement. Coronavirus (COVID-19) Update: FDA Limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. January 24, 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron (accessed June 26, 2022).
13. Ikemori S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604: 553–56.
14. Cameron E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022; 602: 664–70.
15. Rockett R, Bastle K, Maddocks S, et al. Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use. N Engl J Med 2022; 386: 1477–79.
16. Dong J, Zost SJ, Greaney AJ, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol 2021; 6: 1233–46.
17. Luo YM, McNammy PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med 2022; published online Jan 25. https://doi.org/10.1126/scitranslmed.abl8124.
18. Oganesyan V, Damischroder MM, Woods RM, Cook KE, Wu H, D’Accafro WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2021; 114: 1750–55.
19. Oganesyan V, Gao C, Shirinian L, Wu H, D’Accafro WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64: 700–04.
20. Murray DD, Babiker AG, Baker JV, et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). Clin Trials 2022; 19: 52–61.
21. Lundgren JD, Grund B, Barkauskas CE, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 2021; 384: 905–14.
22. National Institutes of Health. Coronavirus (COVID-19) Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/ (accessed May 13, 2022).
23. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65–70.
24. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–54.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.
26. Zhou B, Latouche A, Rocha V, Fine J. Competing risks regression for stratified data. Biometrics 2011; 67: 661–70.
27. Pocock SJ, Armit CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33: 176–82.
28 Somersan-Karayaka S, Mylonakis E, Menon VP, et al. Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19. medRxiv. 2021; published online Jan 27. https://doi.org/10.1101/2021.11.05.21265656 (prepr).

29 Junqueira C, Crespo A, Ranjbar S, et al. Fc-R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 2022; 606: 576–584.

30 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med 2020; 383: 1813–26.

31 Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.1.351 from natural and vaccine-induced sera. Cell 2021; 184: 2348–61.e6.

32 Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 2021; 184: 2939–54.e9.

33 Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 2021; 184: 4220–36.e13.

34 Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med 2022; 28: 1297–1302.